Original from: 360dx
The US Food and Drug Administration has granted Emergency Use Authorization to Healgen Scientific for a point-of-care combination antigen test for COVID-19 and influenza A/B.
The Healgen COVID-19/Flu A&B Ag Combo Rapid Test Cassette is a lateral flow assay that is used for the qualitative detection and differentiation of SARS-CoV-2 and flu A/B nucleocapsid protein antigens in anterior nasal swab samples from individuals with signs and symptoms of respiratory infection within the first five days of symptom onset. The test is approved for use when patients are tested at least twice in three days with at least 48 hours between tests.
Negative results are presumptive and may be confirmed with a molecular assay.
Healgen also received FDA 510(k) clearance earlier this year for its Healgen Rapid COVID-19 Antigen Test, which is a prescription-use lateral flow immunoassay for COVID-19.
Source: Healgen Gets Emergency Use Authorization for COVID, Flu Combo Test
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.